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1. Introduction 
Globally, breast cancer is the most common type of cancer among women, which comprises 
23% of all female cancers that are newly diagnosed in more than 1.1 million women each 
year. Over 411 000 deaths result from breast cancer annually; this accounts for over 1.6% of 
female deaths from all causes. Hyperthermia also called thermal therapy or thermotherapy 
is a type of cancer treatment in which body tissue is exposed to high temperatures. Research 
has shown that high temperatures can damage and kill cancer cells, usually with minimal 
injury to normal tissues. Otherwise, ablation or high temperature hyperthermia is defined as 
the direct application of chemical or thermal therapies to a tumor to achieve eradication or 
substantial tumor destruction. Many ablation modalities have been used, including 
cryoablation, ethanol ablation, laser ablation, and radiofrequency ablation. The most recent 
development has been the use of microwave ablation in tumors. Furthermore, The use of 
breast cancer mammography screening has allowed detecting a greater number of small 
carcinomas and this has facilitated treatment by minimally invasive techniques. Currently, 
physicians test minimally invasive ablation techniques to determine if they will be acceptable 
substitutes for surgical removal of primary breast tumors. Therefore, numerical 
electromagnetic and thermal simulations are used to optimize the antenna design and predict 
heating patterns. A review of different hyperthermia ablative therapies, for breast cancer 
treatment is summarized in this work. Otherwise, advanced computer modeling in high 
hyperthermia treatment and experimental model validation will be referred to in this chapter. 
1.1. Tumor ablation 
Tumor ablation is defined as the direct application of chemical or thermal therapies to a 
tumor to achieve eradication or substantial tumor destruction. The aim of tumor ablation is 
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to destroy an entire tumor by using heat to kill the malignant cells in a minimally invasive 
fashion together with a sufficient margin of healthy tissue, to prevent local recurrence. Many 
ablation modalities have been used, including cryoablation, ethanol ablation, laser ablation, 
and radiofrequency ablation (RFA). The most recent development has been the use of 
microwave ablation (MWA) in tumors [1].  
Nevertheless the local application of heat to treat patients with malignant tumors is not a 
novel concept. The Edwin Smith papyrus describes the topical application of hot oil or 
heated metallic implements that were used approximately 5000 years ago to treat patients 
with tumors [2]. The use of an electrical current to produce thermal tissue necrosis in 
patients with breast carcinoma also is not new: Metallic or clay-insulated electrodes were 
inserted into locally advanced breast tumors in the late 19th century to shrink the tumor and 
reduce pain and bleeding [3]. 
1.2. Principles of tissue damage 
1.2.1. Radiofrequency ablation 
This therapy works by converting radiofrequency waves into heat through ionic vibration. 
Alternating current passing from an electrode into the surrounding tissue causes ions to 
vibrate in an attempt to follow the change in the direction of the rapidly alternating current. 
It is the ionic friction that generates the heat within the tissue and not the electrode itself. 
The higher the current, the more vigorous the motion of the ions and the higher the 
temperature reached over a certain time, eventually leading to coagulation necrosis and cell 
death. The ability to efficiently and predictably create an ablation is based on the energy 
balance between the heat conduction of localized radiofrequency energy and the heat 
convection from the circulation of blood, lymph, or extra and intracellular fluid [4]. The 
amount of radiofrequency produced heat is directly related to the current density dropping 
precipitously away from the electrodes, thus resulting in lower periphery temperatures. It 
can be approximated that the heat generated in a region at distance d from the electrode 
drops as 1/d4. The goal of radiofrequency ablation is to achieve local temperatures that are 
lethal to the targeted tissue. Generally, thermal damage to cells begins at 42°C; and once 
above 60°C, intracellular proteins are denatured, the lipid bilayer melts, and irreversible cell 
death occurs [5]. 
1.2.2. Microwave ablation 
Water molecules are polar, that is, the electric charges on the molecules are asymmetric. The 
alignment and the charges on the atoms are such that the hydrogen side of the molecule has 
a positive charge, and the oxygen side has a negative charge. When an oscillating electric 
charge from radiation interacts with a water molecule, it causes the molecule to flip. 
Microwave radiation is specially tuned to the natural frequency of water molecules to 
maximize this interaction. Temperature is a measure of how fast molecules move in a 
substance, and the vigorous movement of water molecules raises the temperature of water. 
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Therefore, electromagnetic microwaves heat matter by agitating water molecules in the 
surrounding tissue, producing friction and heat, thus inducing cellular death via 
coagulation necrosis [6]. 
1.3. Ablative devices 
1.3.1. Radiofrequency ablation 
The different manufacturers employed various strategies to obtain larger ablation zones [7]; 
there are currently three different manufacturers that offer commercial radiofrequency 
tumor ablation devices in the USA (Boston Scientific, Rita Medical and Valleylab) and an 
additional one in Europe (Celon). Two manufacturers (Boston Scientific and Rita Medical) 
employ multitined electrodes, to increase electrode surface area and volume of tissue heating. 
For multitined electrodes typically an incremental deployment of the tines in stages is used, 
with ablation at each deployment stage for a certain amount of time or until the target 
temperature is achieved to ensure complete ablation of the target volume. Two manufacturers 
use internal electrode cooling via circulation of water or saline to increase ablation zone size 
(Valleylab and Celon). By cooling the electrode, the tissue surrounding the electrode is also 
cooled. The location of maximum temperature is ‘pushed’ further into the tissue, resulting in a 
larger ablation zone size. A similar effect is obtained by infusing saline into the tissue via ports 
in the electrode this method is used by the Starburst Xli™ electrode [8]. 
1.3.2. Microwave ablation 
A variety of probes have been proposed for use in MWA, with the majority being based on a 
coaxial structure due to the deep-seated location of many tumors and the angular symmetry 
of the tumor. Initial antennas based upon a coaxial waveguide structure include designs, 
such as the monopole, dipole and slot antennas, often encased in a polytetrafluoroethylene 
(PTFE) catheter to minimize adhesion of the probe to desiccated ablated tissue. A number of 
challenges, characteristics and trade-offs have been identified in the design of MWA probes. 
Challenges include the reduction of backward heating, minimization of probe diameter and 
impedance matching of the antenna to the surrounding tissue. Trade-offs in design involve 
probe diameter versus maximum application of power and ablation power versus ablation 
time. Early coaxial antennas developed for MWA yielded ablation zones resembling a ‘tear 
drop’, as opposed to the desired spherical shape [9]. More recent MWA probes were designed 
to minimize probe size, maximize ablation zone size, minimize detrimental heating of the 
feedline and yield more spherical lesions, by minimizing impedance mismatch [10-12]. 
2. Clinical applications 
2.1. Radiofrequency ablation 
The first RFA clinical report was published in 1999, Jeffrey et al. [13] treated with RFA a 
small series of five women, aged 38 to 66 years, with locally advanced (stage III) breast 
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cancer or tumors larger than 5 cm. While patients were under general anesthesia and just 
before surgical resection, a 15-gauge insulated multiple-needle electrode (LeVeen needle 
electrode; RadioTherapeutics Corp, Mountain View, Calif) was inserted into the tumor 
under sonographic guidance. The multiple-needle electrode was connected to a RF-2000 
generator (Radio Therapeutics Corp), and a return electrode pad (Valley Lab, Boulder, 
Colo). Radiofrequency energy was applied at a low power by a preset protocol for a period 
of up to 30 minutes. The ablated area measured 0.8–1.8 cm diameter and non-viable tumor 
was found within this area in four patients. 
Izzo et al. [14] used the same RFA electrode in patients with much smaller tumours. Twenty-
six women with a mean cancer size of 18 mm underwent RFA and immediate surgical 
excision. RFA was performed following a predetermined two-phase algorithm. Treatment 
was initiated at 10 watts of power for 2 minutes, after which, power was increased in 5-watt 
increments every minute until tissue impedance rose rapidly and power dropped below 10 
watts, thus indicating complete coagulative necrosis of the target lesion. After a 30-second 
pause, a second phase of treatment was applied, again beginning at 10 watts for 2 minutes 
followed by increases in power of 5 watts per minute until tissue impedance again rose and 
power rolled off. Power (watts) and impedance (ohms) were monitored continuously 
during treatment. The maximum power at the time of increase in the tissue impedance 
preceding power roll off and the total time needed to complete two-phase RFA were 
recorded. NADH diaphorase histochemical analysis showed a residual cancer focus in an 
area adjacent to the needle shaft site in one case, while the remaining patients were treated 
successfully with a complication rate of 4%. 
Burak et al. [15] treated tumours with a mean diameter of 12 mm, creating an ablation zone 
of 26–45 mm and reported one case with surviving malignancy. Viability was assessed using 
cytokeratin 8 ⁄ 18 stain. Under ultrasound guidance, 1% lidocaine was injected around the 
breast tumor for a distance of about 3 cm in all directions surrounding the tumor mass. 
After a 5–10-minute waiting period, a small skin incision was made with a number 11 
surgical blade under aseptic conditions. The 2 cm array RFA probe (Radiotherapeutics, 
Sunnyvale, CA) was inserted under ultrasound guidance and deployed so that the “prongs” 
encompassed the breast tumor. Radiofrequency energy was applied over 2 time periods, 
which were not to exceed a total of 30 minutes. In the first time period, power was set to 10 
W and increased in 5 W intervals every 2 minutes until a rapid increase in impedance 
(ohms) occurred, or when 60 W was reached. If 60 W was obtained, the probe was left in 
place until impedance or a total period of 15 minutes elapsed. In the second time period, the 
application began at 10W and the same titration was followed. 
Hayashi et al. [16] ablated small breast primaries measuring 9 mm median in 22 patients. 
The median ablated diameter was 35 mm, viability was assessed with NADHdiaphorase 
and showed eight failures. In three, the site was at the periphery but in five was in a missed 
untargeted area. Under sterile conditions in the ultrasonography suite, a 15-gauge, 7-array 
StarBurst radioprobe (RITA Medical Systems, Mountain View, California) was placed 
directly into the tumor using sonographic guidance (HDI 3000; Phillips Medical, Bothell, 
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Washington). The prongs were deployed after positioning was confirmed in three 
dimensions using real-time ultrasound. The probe was connected to the RF generator (RITA 
model 1500) with a grounding pad placed on each thigh to complete the electrical circuit. 
The generator was set to automatic, power at 20 W, temperature to 95°C, and ablation time 
set at 15 minutes. The generator was activated and power was delivered incrementally until 
the target temperature was attained and held for the set time. The ablation process was 
monitored with ultrasonography and real time temperature feedback. Vital signs were 
monitored and if the patient reported significant discomfort, the ablation was temporarily 
halted. On completion of the procedure, the tines were retracted and the needle withdrawn. 
Fornage et al. [17] treated 21 breast tumours of < 2 cm and in the subsequent excision 
specimen all targeted cancer foci were ablated with an average diameter of 3.8 cm. One 
patient who had received neoadjuvant chemotherapy was found to have a further 
mammographically and ultrasonically occult viable tumour. A 460-kHz monopolar RF 
electrosurgical generator specifically designed for use with electrosurgical RF probes (RITA 
Medical Systems, Mountain View, Calif) was used in this study. The needle-electrode 
consists of a primary electrode— that is, a 15-gauge stainless-steel cannula with a 
noninsulated distal tip that acts as an electrode—and secondary electrodes, which are 
curved, flexible stainless-steel prongs that are contained within and can be deployed outside 
of the primary electrode. A 50-W model 500 electrosurgical RF generator (RITA Medical 
Systems) with a disposable, seven-array model 70 Starburst needle electrode (RITA Medical 
Systems) was used in the first nine patients. Subsequently, a 150-W model 1500 generator 
(RITA Medical Systems) with a nine-array Starburst XL needle-electrode (RITA Medical 
Systems) was used in 11 patients. Both types of needle-electrodes were 15 cm long. The 
arrays on the Starburst XL needle-electrode can be deployed to a length of 5 cm. 
Thermocouples placed at the tips of four prongs of the seven-array needleelectrode and at 
the tips of five prongs of the nine-array needle-electrode enabled continuous real-time 
monitoring of the temperatures at the tips. A laptop computer with proprietary software 
developed by the manufacturer of the RF ablation equipment was used to graphically 
display, in real time, the curves of the temperatures at the tips, the power of the generator, 
and the impedance of the tissues over time. 
Marcy et al. [18] treated five cancers in four not-fit-for-surgery patients with RFA and had 
one relapse after 4 months. Percutaneous radiofrequency–lumpectomy was performed 
under local analgesia (lidocaine, subcutaneous injection), using ultrasound guidance under 
sterile conditions in the interventional radiology suite. RFA was applied between a large 
neutral electrode, leading to a high electric field line density in the region of the needle tip, 
and the 1.5 mm x 1.1 mm non-isolated needle tip ablation electrode. Thermal lesions were 
always produced with RF power 30 W, at a frequency of 500 kHz, during a 12 min 
application time as recommended by the manufacturer (Elektrotom 104HF; Thermo-
Berchtold Medizinelektronik Gmbh, Tuttlingen, Germany). A controlled interstitial needle 
perfusion of isotonic sterile saline solution (0.9% NaCl) was applied using an infusion pump 
(Perfusor Secura FT; Braun, France). The current flows from the uninsulated perfused 
electrode implanted in the tumour to a grounding pad applied externally to the skin. A 
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feedback system controlling RF power application and saline infusion of the needle 
maintains power delivery. The RFA probe was designed to create a minimum spherical 
ablation volume of 3 cm diameter. Thermocoagulation included the tumour plus at least a 5 
mm margin. The RFA probe was typically positioned parallel to the overlying skin under 
ultrasound guidance, and the procedure was carried out during real-time ultrasound 
monitoring. Ablation zones were visualized as cone-shaped hyperechogenic areas around 
the needle tip, experiencing the temperature increase. Vital signs were monitored and if the 
patient reported significant discomfort, the ablation was temporarily halted. On completion 
of the procedure, the lines were retracted and the needle withdrawn. A small ice pack was 
placed on the wound for up to 24 h after the procedure for comfort. The patient was 
discharged home once stable and free of sedative effects. 
Susini et al. [19] treated three patients who had small breast cancers with RFA and followed 
them with clinical examination, ultrasound, magnetic resonance imaging (MRI) and core 
biopsy. After 18 months no relapses were reported. The 18-G Cool tip RF Radionics (Valley 
Lab, USA) was used to perform RFA, by means of one single electrode, 20-cm length. Local 
anesthesia was performed using a mixture of lidocaine and naropine injected under the 
overlying skin, and around the tumor. With ultrasound guidance, the electrode was inserted 
and its progression was monitored in real-time, allowing the exact positioning of the tip in 
the center of the lesion. Then, the RF generator was switched on and tissue impedance was 
measured. The generator produced RF energy through high-frequency (480 kHz) alternating 
current. When the tissue temperature reached 90°C, ultrasound image showed the “fog 
effect”, in relationship with the vaporization of intracellular water. RF energy was applied 
for a variable time of 8–12 min. 
Oura et al. [20] in their series of 52 patients with breast cancers of mean size 1.3 cm. 
Multifocality, multicentricity and tumour size were thoroughly investigated prior to RFA 
and patients with multiple malignant areas or large tumours were excluded. Patients were 
submitted to ultrasound guided RFA and were subsequently followed with clinical 
examination, ultrasound, MRI and cytology. After a mean follow-up of 18 months no 
relapses were reported. Operation was performed under general anesthesia in all patients. 
After the removal of sentinel node(s), RFA started using a Cool-tip RF needle with an 
uninsulated tip 3 cm in diameter (Valleylab, Boulder, CO). The Cool-tip RF needle was 
inserted into the tumor from the areola under ultrasound guidance. A total of 20-60 mL of 
5% glucose was injected subcutaneously just above the tumor after appropriate insertion of 
the needle was confirmed. The RFA started at 5 watts, raised the output to 10 watts 1 minute 
later, and thereafter increased output continuously in increments of 10 watts at 1 minute 
intervals until either the generator stopped delivering radiofrequency energy due to a 20 
ohms or more impedance increase of the ablated tissue from the base line, or the scheduled 
time which was 30 minutes in the first 29 cases and 15 minutes thereafter when‘break’did 
not occur. 
Medina et al. (2008) [21] treated Twenty-five patients, aged 42 to 89 years with invasive 
breast cancer <4 cm (range 0.9–3.8 cm). Under ultrasound guidance, a 17-gauge probe 
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(Elektrotom 106 HiTT, Berchtold, Germany) was inserted in the center of the tumor. The 
needle electrode was attached to a 500 kHz monopolar RFA generator. RF energy was 
applied to the tissue with initial power setting of 30 W, for three cycles of 3 minutes each. 
The energy was increased with increments of 5 W to a maximum power of 50 W. 
Radiofrequency was delivered until the tumor was completely hyperechoic with the aim of 
obtaining a safety margin of 1 cm around the tumor. Of the 25 patients treated, NADPH 
stain showed no evidence of viable malignant cells in 19 patients (76%), with significant 
difference between tumors <2 cm (complete necrosis in 13 of 14 cases, 92.8%). 
Currently Takayuki [22] et al. treated 49 patients, aged 36 – 82 years and tumor size ≤3.0 cm 
in diameter (range 0.5–3.0 cm) on US examination. Under US guidance, the 17-gauge 
ValleylabTM RF Ablation System with Cool-tipTM Technology (Covidien, Energy-Based 
Devices, Interventional Oncology, Boulder, CO) was inserted in the center of the tumor. The 
needle electrode was attached to a 500-kHz monopolar RF generator capable of producing 
200-W power. Tissue impedance was monitored continuously using circuitry incorporated 
into the generator. RF energy was applied to tissue with an initial power setting of 10 W and 
subsequently increased with increments of 5 W each minute to a maximum power of 55 W. 
The power setting was left at this point until power ‘rolloff’ occurred. Power rolloff implies 
that there is an increase in the tissue impedance. When this occurs, the power generator will 
shut off, stopping the flow of current and further tissue coagulation. After waiting 30–60 s, 
the second phase was started at 75% of the last maximum power until a second rolloff 
occured. Radiofrequency was applied until the tumor was completely hyperechoic. 
Following RF ablation, standard tumor resection was achieved with either a wide local 
excision or mastectomy according to the preference of the patient. Of the 49 treated patients, 
complete ablation was recognized in 30 patients (61%) by H&E staining and/or NADH 
diaphorase staining. A summary is presented in tables 1-4. 
 
Authors Patients Age range 
Tumor Size 
(cm) 
Jeffrey 5 38-66 4-7 
Izzo 26 37-78 0.7-3.0 
Burak 10 37-67 0.5-2.0 
Hayashi 22 60-80 0.5–2.2 
Fornage 20 38-80 ≤2.0 
Marcy 4 79-82 1.8-2.3 
Susini 3 76-86 <2.0 
Oura 52 37-83 0.5-2.0 
Medina 25 42-89 0.9 - 3.8 
Takayuki 49 20-90 ≤3.0 
Table 1. Patient and tumor characteristics in ten studies on radiofrequency ablation for breast cancer 
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Authors Electrode Probe  Generator 
Jeffrey 15-g multineedle LeVeen  RF-2000 Radio Therapeutics 
Izzo 15-g multineedle LeVeen  RF-2000 Radio Therapeutics 
Burak 
2 cm array probe 
Radio therapeutics 
 Not mentioned 
Hayashi 
15-g, 7 cm array 
Starburst RITA 
 RITA-1500 RITA 
Fornage 
7-array / 15-g, 9 cm array Starburst 
RITA 
 RITA-500 / RITA-1500 
Marcy 
1.5 mm · 1.1 mm non-isolated tip 
Elektrotom 
 Elektrotom 104HF 
Susini 18-G Cool tip RF Radionics  Not mentioned 
Oura 3 cm Cool-tip uninsulated Valleylab  Not mentioned 
Medina 17-g Elektrotom 106, Germany  Monopolar 200 W 
Takayuki 
17-g Valleylab RF Ablation System 
with Cool-tip 
 Monopolar 200 W 
Table 2. Devices in ten studies on radiofrequency ablation for breast cancer 
 




Jeffrey 480-kHz Impedance 46.8 - 70.0 Ultrasound 
Izzo 480-kHz Impedance Not mentioned Ultrasound 
Burak 460 kHz Impedance Not mentioned Ultrasound 
Hayashi 460 KHz NO 95  
Fornage 461 KHz NO 90 and 95 
Ultrasound & 
Doppler 
Marcy 500 kHz NO Not mentioned Ultrasound 
Susini 480 kHz NO 90 Ultrasound 
Oura Not mentioned Impedance > 60 Ultrasound 
Medina 500 KHz NO 70 - 80 Ultrasound 
Takayuki 500 KHz Impedance Not mentioned Ultrasound 
Table 3. Technical settings in ten studies on radiofrequency ablation for breast cancer 
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Authors Anesthesia Fail Complications 
Jeffrey General 1 0 
Izzo General 1 1 
Burak Local 1 1 
Hayashi Local 3 1 
Fornage General 1 0 
Marcy Local 1 0 
Susini Local 0 0 
Oura General 0 1 
Medina General 6 1 
Takayuki General 18 5 
Table 4. Results in ten studies on radiofrequency ablation for breast cancer 
2.2. Microwave ablation 
Three studies on microwave ablation have been published [23-25]. A pilot safety (phase I) 
study included ten patients with core needle biopsy-proven invasive breast carcinoma (T1–
T3 tumors) [23]. Of the eight patients who responded, 82–97% tumor cell kill was found, 
confirmed by M30 immunohistochemistry. Image guidance was performed using US. Five 
to 27 days after treatment patients underwent mastectomy. The same group also published 
another article in which 21 patients with T1–T2 invasive breast carcinoma underwent 
microwave ablation [24]. In 68% of the patients, histologic evidence of tumor necrosis was 
present. Finally, this group published a dose-escalation study [25].  
Twenty-five patients with core needle biopsy-proven invasive breast carcinoma (T1–T2 
tumors) were included. US provided image guidance; there was no correlation between 
clinical/ultrasonographic size changes and pathologic tumor response. In 68% of the cases 
there was evidence of pathologic response using H&E staining. In two cases complete 
ablation was reached; these patients received the highest temperature dose. Complications 
mentioned were mild pain during treatment, skin burn, and short-lived erythema of the 
skin.  
2.3. Summary 
In RFA several different devices from different manufacturers were used in different ways 
for varying periods of time and varied protocols, so not surprisingly, they reported quite 
heterogeneous results. Nevertheless successful cases for different protocols were obtained 
for smaller tumors with a low failures and complication rate. In addition the clinical MWA 
is limited to external techniques and currently the greatest amount of interstitial research 
was conducted in the liver tissue. The generation of an appropriately sized ablation zone, 
long treatment times, insufficient interoperative imaging modalities and performance in the 
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vicinity of vascular structures are limitations of current devices. An ideal ablative 
technology would ensure complete destruction of all malignant cells with no significant side 
effects or complications. 
3. Advanced computer modeling in breast cancer hyperthermia treatment 
In this section, we present a computer modeling for microwave high hyperthermia in breast 
cancer treatment. Computational electromagnetic (CEM) or electromagnetic modeling 
employs numerical methods to describe propagation of electromagnetic waves. It typically 
involves the formulation of discrete solutions using computationally efficient 
approximations to Maxwell's equations. There are three techniques of CEM: the finite-
difference time-domain (FDTD), the method of moments (MOM), and the finite element 
method (FEM), which has been extensively used in simulations of cardiac and hepatic 
radiofrequency (RF) ablation [26]. A FEM model was used in this work because it can 
provide users with quick, accurate solutions to multiple systems of differential equations 
and therefore, they are well suited to solve heat transfer problems like ablation [27]. 
Numerous MWA antenna designs specifically targeted for MWA cardiac and hepatic 
applications have been reported [20-24], but they have not been used to treat breast cancer. 
These designs have been focused largely on thin, coaxial-based interstitial antennas [28], 
which are minimally invasive and capable of delivering a large amount of electromagnetic 
power. These antennas can usually be classified as one of three types (dipole, slot, or 
monopole) based on their physical features and radiation properties [29]. On the other hand, 
several researchers are investigating non-invasive microwave hyperthermia for treatment of 
breast cancer [30]. 
3.1. Equations 
The frequency-dependent reflection coefficient can be expressed logarithmically as: 
 Γ(݂) = 10 ∙ logଵ଴ ቀ௉ೝ	(௙)௉೔೙ ቁ ሾ݀ܤሿ (1) 
where, Pin is the input power and Pr indicates the reflected power (W). SAR represents the 
amount of time average power deposited per unit mass of tissue (W/kg) at any position. It 
can be expressed mathematically as: 
 
2
/SAR E W Kg

       (2) 
where, σ is tissue conductivity (S/m), ρ is tissue density (kg/m3) and E is the electric field 
[56]. The SAR takes a value proportional to the square of the electric field generated around 
the antenna and is equivalent to the heating source created by the electric field in the tissue. 
The SAR pattern of an antenna causes the tissue temperature to rise, but does not determine 
the final tissue temperature distribution directly. The tissue temperature increment results 
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from both power and time. MW heating thermal effects can be roughly described by Pennes’ 
Bioheat equation [31]: 
 ∇ ∙ 	 (−݇∇ܶ) = ߩ௕ܥ௕߱௕( ௕ܶ − ܶ) + ܳ௠௘௧ + ܳ௘௫௧ (3) 
where k is the tissue thermal conductivity (W/m°K), ρb is the blood density (Kg/m3), Cb is the 
blood specific heat (J/Kg°K), ωb is the blood perfusion rate (1/s). Tb is the temperature of the 
blood and T is the final temperature. Qmet is the heat source from metabolism and Qext an 
external heat source. The major physical phenomena considered in the equation are 
microwave heating and tissue heat conduction. The temperature of the blood is 
approximated as the core temperature of the body. Moreover, in ex vivo samples, ωb and 
Qmet can be neglected since no perfusion or metabolism exists. The external heat source is 
equal to the resistive heat generated by the electromagnetic field. 
3.2. Material properties 
The computer antenna model used in this work is based on a 50Ω UT-085 semirigid coaxial 
cable. The entire outer conductor is copper, in which a small ring slot of width is cut close to 
the short-circuited distal tip of the antenna to allow electromagnetic wave propagation into 
the tissue. The inner conductor is made from silver-plated copper wire (SPCW) and the 
coaxial dielectric is a low-loss polytetrafluoroethylene (PTFE). The length of the antenna also 
affects the power reflection and shape of the SAR pattern. Furthermore, the antenna is 
encased in a PTFE catheter to prevent adhesion of the antenna to desiccated ablated tissue. 
Dimensions and thermal properties of the materials and breast tissue, which were taken 
from the literature [32], are listed in Table 5 and 6. 
 
Parameter Value 
Center conductor diameter 0.51 mm 
Dielectric diameter 1.68 mm 
Outer conductor diameter 2.20 mm 
Diameter of catheter 2.58 mm 
Power 10 W 
Frequency 2.45 GHz 
Electrical Conductivity of breast 0.137 S/m 
Thermal conductivity of breast 0.42 W/m K 
Specific heat of blood 3639 J/Kg/k 
Blood perfusion rate 0.0036 s-1 
Electrical conductivity of tumor 3 S/m 
Thermal conductivity of tumor 0.5 W/m K 
Table 5. Dimensions and properties for the materials and tissue. 
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Material Relative permittivity 
Inner dielectric oft he coaxial cable 2.03 
Catheter 2.60 
Breast tissue 5.14 
Tumor 57 
Table 6. Relative permittivity for the materials and tissue. 
Figure 1 shows the axial schematics of each section of the antenna and the interior 
diameters. 
 
Figure 1. Cross section and axial schematic of the coaxial slot antenna. 
 
High Temperature Hyperthermia in Breast Cancer Treatment 95 
A finite element method computer models were developed using COMSOL Multiphysics 
4.0 commercial software. One of the models assumed that the coaxial slot antenna was 
immersed only in homogeneous breast tissue; the other model assumed that the antenna 
was immersed only in breast cancer. The coaxial slot antenna exhibits rotational symmetry 
around the longitudinal axis; therefore axisymmetric models, which minimized the 
computation time, were used. The inner and outer conductors of the antenna were modeled 
using perfect electric conductor boundary conditions and boundaries along the z axis were 
set with axial symmetry.  
All boundaries of conductors were set to perfect electric conductor (PEC). Boundaries along 
the z axis were set with axial symmetry and all other boundaries were set to low reflection 
boundaries. Figure 2 shows the geometry of the antenna model with details near its slot; 
since the model is axisymmetric, only a half of the antenna geometry structure is shown [33]. 
 
Figure 2. Axisymmetric model in the vicinity of the tip of the coaxial slot antenna. The vertical axis (z) 
corresponds to the longitudinal axis of the antenna; while the horizontal axis (r) corresponds to radial 
direction. All units are in meters. 
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3.3. Results 
Figure 3 shows the temperature distribution in normal adipose-dominated tissue [34]. The 
reflection coefficient calculated for the frequency at 2.45 GHz was -2.82 dB, the maximum 
temperature was 116.03 ºC, and the ablation zone radius was 53 mm. The isotherm was 
considered at 60 ºC because ablation is produced above this temperature [35]. Figure 4 
shows the temperature distribution in breast cancer tissue. The reflection coefficient 
calculated for the frequency at 2.45 GHz was -6.38 dB, the maximum temperature was 












Figure 3. Temperature distribution of normal adipose-dominated breast tissue at a microwave power 
output of 10 W. The isotherm at 60 ºC is highlighted. The illustration shows half the plane through the 
symmetry axis. Vertical axis (z) corresponds to the longitudinal axis of the antenna; horizontal axis (r) 
corresponds to radial direction. 
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Figure 4. Temperature distribution of breast cancer tissue at a microwave power output of 10 W. The 
isotherm at 60 ºC is highlighted. The illustration shows half the plane through the symmetry axis. 
Vertical axis (z) corresponds to the longitudinal axis of the antenna; horizontal axis (r) corresponds to 
radial direction. 
4. Conclusion 
In RFA for high temperature hyperthermia therapy in breast cancer several devices from 
different manufacturers were used in diverse ways for varying periods of time and assorted 
protocols, therefore exist heterogeneous results. Nevertheless successful cases for were 
obtained for smaller tumors with a low failures and complication rate. On the other hand 
the effect of MWA on malignant and normal adipose-dominated tissues of the breast was 
simulated using an axisymmetric electromagnetic model. This model can analyze the 
heating patterns using the bioheat equation. The results from computer modeling 
demonstrated that, effectively, the difference in dielectrical properties and thermal 
parameters between the malign and normal adipose-dominated tissue could cause the 
preferential heating on tumor during MWA. Even though electromagnetic high temperature 
hyperthermia requires further research, it is a promising minimally invasive modality for 
the local treatment of breast cancer. 
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